Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
Holding APLT?
Track your performance easily
APLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.79 - $9.39
Previous Close$7.85
Volume9.65M
Average Volume (3M)2.08M
Market Cap
$901.54M
Enterprise Value$779.56M
Total Cash (Recent Filing)$122.20M
Total Debt (Recent Filing)$215.00K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Nov 07, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding114,846,271
10 Day Avg. Volume6,145,255
30 Day Avg. Volume2,079,249
Standard Deviation0.37
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)12.46
Price to Sales (P/S)53.44
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.34K
Enterprise Value/Gross Profit78.01
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$12.33Price Target Upside54.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Applied Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataThe totality of data are supportive of approval, including the significant reduction in galactitol and consistent improvements across several clinical outcomes, which are now strengthened with the updated cognition data analysis.
Mechanism And BiomarkersThe effect on a biomarker (galactitol) is considerable with an established relationship with disease severity.
Regulatory ProgressTentative AdCom scheduling in galactosemia is a positive step in advance of PDUFA.
Bears Say
Clinical ConcernsArimoclomol has previously received a CRL based on a litany of concerns around endpoint validity, statistical methods, and conflicting evidence.
Pipeline ChangesThe company has removed the diabetic peripheral neuropathy indication for AT-001 from its pipeline chart.
Regulatory IssuesUpdates to the data included in their NDA/MAA filings for govorestat in galactosemia were needed due to calculation errors made by a vendor.
---
Ownership Overview
14.80% Insiders
10.34% Mutual Funds
65.78% Other Institutional Investors
9.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLT FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was $1.79 and its highest was $9.39 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Currently, no data Available
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Aug 07, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.035.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -$0.16.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 114,846,270 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 1.639%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Among the largest hedge funds holding Applied Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Applied Therapeutics Inc’s shares valued at 37M.
---
Applied Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (54.13% Upside)
$12.33 (54.13% Upside)
Blogger Sentiment
Bullish
APLT Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 40.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
296.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
192.76%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
APLT Stock 12 Month Forecast
Average Price Target
$12.33
▲(54.13% Upside)
Technical Analysis
Best Analysts Covering APLT
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+68.68%
reiterated a buy rating 24 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +68.68% per trade.
---